Introduction
Picornaviruses (PVs) are a diverse group of human pathogens which cause a wide variety of disease syndromes. In terms of clinical significance, enteroviruses (EVs) and human rhinoviruses (HRVs) are the most clinically important genera of PVs, causing millions of infections each year. Infections due to EVs range in severity from asymptomatic to aseptic meningitis, encephalitis, paralysis, pneumonia and myocarditis (Bowles et al., 1986 (Bowles et al., , 1987 Easton & Eglin, 1988; Leslie et al., 1989) . Although infections of the central nervous system and heart are of greatest concern, these viruses are multi-systemic in their tissue tropisms and virulence. For this reason, the clinical diagnosis of EV infection can be complicated by the non-specific nature of many of the syndromes, which often makes them indistinguishable from diseases caused by bacteria and other viruses.
HRVs are the major causative agents of the common cold (Couch, 1985) . Although infection with HRVs is usually limited to the upper respiratory tract, they can infect the lower respiratory tract (Krilov et al., 1986; Monto et al., 1987) . In one study, 65~ of infected individuals who were 40 or more years of age had lower respiratory tract infections due to HRVs (Monto et al., 1987) . HRVs have also been isolated from a high percentage of children and infants hospitalized with lower respiratory tract infections (Krilov et al., 1986) . Finally, HRVs are known to exacerbate episodes of bronchitis and asthma (Gregg, 1983) . With the development of drugs such as R61837 which have been recently shown to suppress colds in vivo yet are highly specific for HRVs (A1-Nakib et al., 1989) , it is imperative to be able to diagnose HRV infections rapidly.
The broad antigenic diversity among the nearly 70 different serotypes of EVs and over 100 different serotypes of HRVs has made immunoassays impractical (Yolken & Torsch, 1980 , 1981 Dearden & A1-Nakib, 1987) . Nucleic acid hybridization assays have been used but they lack sensitivity (Rotbart et al., 1984; A1-Nakib et al., 1986; Bruce et al., 1989) . Despite its suboptimal sensitivity, tissue culture remains the mainstay of the laboratory diagnosis of EVs and HRVs.
The polymerase chain reaction (PCR; Saiki et al., 1988) has been used to detect pathogen-specific nucleic acids from viruses such as human immunodeficiency virus type 1 (Kwok et al., 1987) , human T-cell lymphotropic virus type 1 (Duggan et al., 1988) , human cytomegalovirus (HCMV) (Demmler et al., 1988; Shibata et al., 1988; Olive et al., 1989a, b) and PVs (Gama et al., 1988 (Gama et al., , 1989 Torgersen et al., 1989; Hyypifi et at., 1989) . However, the PCR assays which have been described for PVs have either not successfully differentiated EVs and HRVs (Gama et aL, 1989; Hyypi/i et al., 1989) or have suffered from a lack of specificity (Hyypi/i et al., 1989) . The assays described thus far have not been tested directly on clinical specimens containing wild-type virus.
We have therefore developed a PCR assay, using primers which detect and differentiate between EVs and HRVs in clinical specimens on the basis of the size of the PCR product. In this report, we demonstrate the specificity of the assay for this group of viruses, as well as its ability to detect wild-type clinical isolates of EVs and HRVs from a variety of clinical specimens. The use of this PCR assay for detection and differentiation of PVs should greatly aid in the clinical management of disease due to PVs.
Methods
Clinical specimens. Either nasal swabs or throat washings were taken from patients presenting with respiratory infections. Clinical specimens were processed immediately by inoculation onto Ohio HeLa or human C16 cells (Phillpotts, 1983) for isolation of HRVs and coronaviruses respectively. HRVs were also examined for acid lability after isolation. Influenza virus isolates were obtained following growth in embryonated eggs (Kendal et al., 1985) . Cerebrospinal fluids (CSF) and stool swabs were taken from patients presenting with various symptoms possibly due to enterovirus infection. Stool swabs were placed in 2 ml of tissue culture medium and, along with CSF specimens, processed for isolation of virus by inoculation onto Vero, HEp-2 or HeLa cells. EVs were typed using intersecting hyperimmune serum pools A to H obtained from the World Health Organization (WHO). Standard strains of EVs and HRVs were obtained from Dr D. A. J. Tyrrell at the MRC Common Cold Unit, Salisbury, U.K.
Synthetic oligonucleotide primers. The mixed primer OL68-1 (5' GGTAAQTTCCACCACCANCC 3') is complementary to the genomic sense RNA at positions 1058 to 1077 in the VP2 region of HRV-1B. The OL68-1 primer contains degeneracies at positions 6 and 18 (Q is either T or C; N is A, G, C or T). The primer OL24 (5' CTACTTTGGGTGTCCG 3') is complementary to antigenomic sense RNA at positions 542 to 567 in the 5'-non-coding region of HRV-1B. The degree of homology exhibited by the primers to known EV and HRV sequences is shown in Fig. 1 (M. A. Khan & G. Stanway, unpublished results) . The alkaline phosphatase-labelled oligonucleotide probe, PV. 1 (5' AGATTGT-TATCATAAAGCGA 3'), for detection of poliovirus PCR products, was homologous to nucleotides 607 to 626 of poliovirus type I (Toyoda et al., 1984) . All oligonucleotides were purchased from Genetic Designs.
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nucleic acid extraction. Vanadyl ribonucleoside complex was added to a final concentration of 10 mM. As a carrier, 1.0 ~tg of phenol-extracted yeast tRNA was added. The samples were extracted with an equal volume of phenol saturated with TE buffer (10 mM-Tris-HC1 pH 7-5, 1 mM-EDTA). The phenol phase was back-extracted with 100 ~tl of sterile water and the aqueous phases were combined. The aqueous nucleic acid was extracted three more times with phenol-TE, followed by two extractions with equal volumes of chloroform. The nucleic acid was precipitated by addition of 0.1 volume of sterile 3 M-sodium acetate (pH 6.5) and 2.5 volumes of 95 ~ ethanol, followed by refrigeration at -70 °C for 15 min. The nucleic acid was pelleted by centrifugation in a microfuge for 5 min and the pellet washed once with 70~ ethanol. The pellet was dried under vacuum and dissolved in 50 ktl of sterile water. The nucleic acid from each sample was extracted in triplicate and processed for cDNA synthesis and amplification.
Reverse transcription. Synthesis of cDNA was performed in a reaction mixture containing 25 Ftl of viral nucleic acid, 8 p.l of 5 x reverse transcriptase buffer (200 mM-Tris-HCI pH 8.3, 375 mM-KC1, 50 mM-dithiothreitol, 15 m~-MgC12), each dNTP at 0.5 mM, 40 units RNAguard (Pharmacia), 1 pl of OL68-1 primer stock (1-0 A260 units/ml) and 200 units of Moloney murine leukaemia virus reverse transcriptase (Bethesda Research Laboratories) in a total volume of 40 ~tl. The reaction was incubated at 37 °C for 1 h and was terminated by the addition of 4 I-tl of 3 ~-sodium acetate pH 6.5 and 100 I.d of 95 ethanol. The mixtures were refrigerated at -70 °C for 15 min, pelleted and the cDNA was dissolved in 50 I.d of TE buffer.
Polymerase chain reaction. For PCR, 15 p.1 of the eDNA was combined with 10 I.tl of 10 x Taq salts (500 mM-KC1, 100 mM-Tris-HC1 pH 8.3, 25 mM-MgC12, 0.1 ~ gelatin), 10 ~tl of 8 mM-dNTP stock (2 mM each dNTP), 2 ~tl each of OL24 and OL68-1 primer stocks (1.0 Az6 o units/ml each), 60 lal of water and 2.5 units of Thermus aquaticus DNA polymerase (Perkin-Elmer Cetus). The mixture was amplified by 30 successive cycles of heating at 94 °C for 2 min, renaturing at 50 °C for 2 min and polymerizing at 72 °C for 3 min. A further unit of enzyme was added after 15 cycles. The PCR products were analysed by Tables 2 and 3 are Hybridization with an alkaline phosphatase-labelled probe. Portions (50 ~tl) of the products of the PCR reactions were combined with 50 pl of 0-6 M-NaOH and incubated at room temperature for 15 min. The denatured DNA was applied to a nylon filter using a filtration manifold and the samples were neutralized by washing each well with 100 pl of 2 M-ammonium aceta~.e. The filters were heated in a vacuum oven for 2 h. The filters were prehybridized for 15 min at 45 °C in buffer containing 5 x SSC (1 × is 0.15 M-NaC1, 0-015 M-sodium citrate), 1% SDS and 0-5% bovine serum albumin. The filters were hybridized for 15 min at 45 °C in the same buffer containing 50 pl of a 0.4 ~tM stock of probe. The filters were washed twice with 100 ml of 1% SDS in 1 x SSC at 45 °C, followed by two washes in 100 ml each of 1% Triton X-100 in 1 x SSC at 45 °C. Finally, the filters were washed in 1 × SSC at room temperature.
The washed filters were immersed in 7.5 ml of alkaline phosphatase buffer (100 mM-Tris HC1 pH 8.5, 100 mM-NaC1, 100 mM-ZnCI2) containing 33pl of Nitro Blue tetrazolium solution (75mg/ml in dimethylformamide) and 25~tl of 5-bromo-4-chloro-3-indolyl phosphate solution (50 mg/ml in dimethylformamide). The colour reaction was allowed to proceed for 4 h and terminated by washing in distilled water.
Results

Detection of standard virus strains
S t a n d a r d s t r a i n s o f E V s a n d H R V s w e r e a m p l i f i e d , a n d t h e P C R p r o d u c t s w e r e d e t e c t e d b y gel e l e c t r o p h o r e s i s . A s s h o w n in Fig. 2 , t h e E V s t e s t e d g a v e rise to a c h a r a c t e r i s t i c P C R p r o d u c t a p p r o x i m a t e l y 650 b p in l e n g t h . I n c o n t r a s t , H R V s t r a i n s g a v e rise to a P C R p r o d u c t o f a p p r o x i m a t e l y 530 bp, u s i n g t h e O L 2 4 / 6 8 -1 p r i m e r s . T a b l e 1 s u m m a r i z e s t h e r e s u l t s o f t h e P C R a s s a y o n s t a n d a r d s t r a i n s o f H R V s , p o l i o v i r u s e s , c o x s a c k i e - viruses (CV) and echoviruses, as well as several unrelated viruses and cell lines. With one exception, the characteristic P C R product was seen for all of the PVs tested. Echovirus 22, however, did not amplify using this assay. In contrast to the P C R assay previously reported by Hyypi~i et al. (1989) , the OL24 and OL68-1 primers did not give rise to spurious amplification products when tested on herpes simplex virus (HSV), H C M V , adenovirus (Ad), rotavirus, HeLa cell DNA, HEp-2 cell D N A or Vero cell D N A (Fig. 3) . Only PVs were amplified and detected.
Detection limits of the PCR assay
In order to determine the amount of virus which could be detected in clinical samples, a titrated stock of poliovirus was serially diluted and added to a negative stool or CSF specimen. The viral nucleic acid was then extracted, reverse-transcribed and amplified. Fig. 4 shows that 1 p.f.u, of virus could be detected on ethidium bromidestained agarose gels regardless of the nature of the clinical specimen. Previous studies have reported comparable sensitivities using titrated virus stocks ( G a m a et Torgersen et al., 1989) .
Detection of HR V in patients with respiratory infections
Nucleic acids from either nasal swabs immersed in tissue culture medium or nasal washings were extracted and subjected to P C R analysis. As shown in Fig. 2 , the characteristic 530 bp P C R product was detected from patients infected with wild-type HRVs. The P C R assay was applied to 28 specimens taken from patients with respiratory infections from whom HRVs had been isolated (Table 2 ). HRVs were detected in 27 of these patients by PCR. In cases where similar respiratory infections were caused by coronaviruses, influenza virus type A or respiratory syncytial virus (RSV), the P C R assay was uniformly negative.
Detection of enteroviruses from clinical specimens
EVs are known to be causative agents of aseptic meningitis and encephalitis (Melnick, 1985) . During the early acute phase of infection, infectious virus can sometimes be isolated from the CSF whereas, in the later stages of infection, virus can also be isolated from stool. In cases of myocarditis, however, virus is rarely isolated, presumably due to low numbers of infectious particles (Leslie et al., 1989) . Specimens taken from patients hospitalized for confirmed EV infections were analysed by P C R along with specimens taken from patients with similar pathologies which were either verified or suspected of being caused by infection with viruses other than PVs (Table 3) . In all cases, the characteristic 650 bp P C R product was detected after amplification of patients suffering from EV-mediated disease. The procedure used in this study was suitable for a variety of clinical specimens, including stool, CSF and pericardial fluid. Cases of aseptic meningitis caused by either CVs or the vaccine strain of poliovirus 2 were clearly detected (Fig. 2) . In two other patients with aseptic meningitis, CVs were detected in stool cultures (Fig. 2) . Significantly, coxsackievirus B2 (CBV2) isolated from the pericardial fluid of a patient who had suffered a myocardial infarction was also detected by P C R assay (Fig. 2) . The P C R was unreactive with specimens taken from patients with similar pathologies containing non-PV viral agents.
Hybridization with a poliovirus-specific probe
The identity of poliovirus P C R products was verified by hybridization to an alkaline phosphatase-labelled oligo- Vaccine strain. § The diagnosis of subacute sclerosing panencephalitis (SSPE) was based on high titres of anti-measles antibody in both serum and CSF.
II The patient specimen was sent for investigation into possible viral causes.
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CBV4 * * * * * * * * * C * * * * T * * * T * CAV9 * * * * * * * * * C * * * * T * * * T * CAV21 C-¢~******* C C * * * T * * * T * nucleotide probe (PV.1) specific for a conserved sequence of the 5'-non-coding region of polioviruses (Fig.  5 ). This sequence is not found in HRVs. The PV. 1 probe hybridized specifically to P C R products obtained by amplification of poliovirus types 1, 2 and 3 (Fig. 6) . As can be seen in Fig. 5 , however, the PV. 1 probe sequence shows considerable mismatch with the sequences of other characterized EVs. The identity of the P C R product obtained by amplification of the CSF material from a patient with aseptic meningitis due to poliovirus type 2, was confirmed with the PV. 1 probe (Fig. 6 ). In contrast, a similar case of meningitis caused by CBV3 was unreactive with the PV. 1 probe (Fig. 6 ). The PV. 1 probe did not detect any of the other EVs tested, presumably owing to the heterogeneity of this region among EVs (unpublished data).
D i s c u s s i o n
Efforts to detect and differentiate PVs directly from clinical samples by using nucleic acid hybridization techniques have been largely unsuccessful. Bruce et al. (1989) have shown that, although radioactively labelled synthetic oligonucleotide probes homologous to the 5' untranslated region of H R V s can be used to detect most k n o w n serotypes, the sensitivity can vary significantly depending on the viral isolate. In addition, the radioactive label used is unsuitable for routine usage. Alkaline phosphatase-labelled probes have been used as an alternative but are even less sensitive (Rotbart et al., 1988) . More recently, Petitjean et al. (1990) have used radioactively labelled riboprobes homologous to the 5' non-coding region of EVs. Although virus could be detected in most stool specimens, the detection of EVs in CSF again showed low sensitivity. The P C R assays described thus far have been unable to give a simple, clear differentiation between EVs and HRVs, nor have they been applied directly to clinical samples ( G a m a et al., 1989; Torgersen et al., 1989; Hyypi~i et al., 1989) . The specificity of antiviral drugs for treatment of respiratory disease makes it imperative to be able to detect and differentiate infections caused by H R V s and EVs directly on clinical specimens since severe respiratory infections can be caused by both viral groups. In addition, acute diseases such as aseptic meningitis or encephalitis require rapid diagnosis for effective clinical management.
D. M. Olive and others
Therefore, we have developed a PCR assay which detects and differentiates PVs directly from clinical specimens. The OL24 primer sequence is derived from a highly conserved region of the 5' non-coding region of the PV genome. The OL68-1 primer is built around a highly conserved stretch of three tryptophan codons (UGG) found in the VP2 region of the PV genome. Using these primers, we have been able to exploit the observation that the 5' non-coding regions of EVs are approximately 120 bp longer than that of HRVs.
The PCR assay detected and differentiated all serologically identified EVs or HRVs tested with the exception of echovirus type 22. The unreactivity of echovirus type 22 in our assay is not surprising, however, since other studies which have tested probes for PV detection have been uniformly unreactive with echovirus type 22 Hyypi~i et al., 1989) . Auvinen et al. (1989) have shown that the nucleotide sequence of echovirus type 22 diverges significantly from that of other PVs. Presumably this is the cause of the unreactivity of echovirus type 22 in our and other PCR and hybridization assays.
Previously, PCR sensitivity has been determined on viral stocks rather than clinical samples. We have shown here, however, that as little as 1 p.f.u, of virus could be detected in CSF or stool samples. This level of sensitivity is sufficient for clinical application. The conditions described here for nucleic acid extraction, reverse transcription and amplification were suitable for all types of clinical samples tested.
For detection of PV-mediated infections, we have relied primarily on the electrophoretic detection of specific sizes of PCR products without further identification by hybridization, restriction enzyme digestion or DNA sequencing. Although we have been able to use a probe for identity confirmation of poliovirus PCR products, this technique is not generally applicable to PV PCR confirmation as much of the region of the viral genome flanked by the OL24/OL68-1 primers shows significant variability among PVs. Torgersen et al. (1989) have used restriction enzyme digestion patterns of PCR products obtained after amplification as a means of serotyping HRVs. Owing to the large number of PVs, as well as the high degree of sequence variability in the region amplified in our assay, mapping with restriction enzymes would be impractical on unknown virus isolates. Furthermore, owing to the limited amount of sequence information available for the more than 170 serotypes of PVs, it is likely that not even DNA sequencing would definitively identify the PCR products as PV-derived. Despite this limitation, we have not observed spurious amplification of any of the heterologous samples examined and the PCR assay resulted in products of the expected size for almost every HRV or EV tested.
By applying the PCR assay to respiratory illness, 27 of 28 wild-type HRVs isolated from nasal swabs were correctly identified. The single HRV not identified probably had a variant nucleic acid sequence at the site of one of the primers. Similarly, EV isolation-positive CSF fluids and stool specimens taken from patients with aseptic meningitis gave rise to the EV-specific 650 bp PCR product. None of the pathologically similar cases from which heterologous viruses had been isolated were amplified.
Significantly, CBV2 was detected in the pericardial fluid of a patient who had suffered a myocardial infarction. CVs have long been suspected of playing a significant role in myocarditis, but definitive data have been lacking due to the low recovery rates of virus from pericardial fluids (Melnick, 1985; Leslie et al., 1989) . The ability to detect virus in pericardial fluid using the PCR assay should facilitate a better definition of the role played by these viruses in cardiac disease.
In summary, even in the absence of sequence confirmation, we conclude that the assay is specific for PVs and, in addition, will differentiate infection by EVs and HRVs. The PCR assay described here is also rapid and can be completed in a single day. Indeed, the rapid detection and differentiation of PVs using the PCR assay should allow better clinical management of PV-mediated disease.
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